(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 November 2025 (27.11.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/242583 A1

(51) International Patent Classification:
A61K 9/14 (2006.01) *A61K 31/00* (2006.01)
A61K 9/20 (2006.01) *A61K 9/28* (2006.01)

(21) International Application Number:
PCT/EP2025/063648

(22) International Filing Date:
19 May 2025 (19.05.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
24177850.5 24 May 2024 (24.05.2024) EP

(71) Applicant: **BAYER CONSUMER CARE AG** [CH/CH]; Peter Merian-Str. 84, 4052 Basel (CH).

(72) Inventors: **ANLAHR, Johanna**; c/o Bayer Aktiengesellschaft, Kaiser-Wilhelm-Allee 1, 51373 Leverkusen (DE). **PREUSS, Andre**; c/o Bayer Aktiengesellschaft, Kaiser-Wilhelm-Allee 1, 51373 Leverkusen (DE). **WINTER, Gabriele**; c/o Bayer Aktiengesellschaft, Kaiser-Wilhelm-Allee 1, 51373 Leverkusen (DE). **TORGE-FRANZEN, Afra**; c/o Bayer Aktiengesellschaft, Kaiser-Wilhelm-Allee 1, 51373 Leverkusen (DE). **BODE, Corinna**; c/o Bayer Aktiengesellschaft, Kaiser-Wilhelm-Allee 1, 51373 Leverkusen (DE). **KARL, Maximilian Franz Ludwig**; c/o Bayer Aktiengesellschaft, Kaiser-Wilhelm-Allee 1, 51373 Leverkusen (DE). **SCHULTZE-MOSGAU, Marcus-Hillert**; c/o Bayer Aktiengesellschaft, Kaiser-Wilhelm-Allee 1, 51373 Leverkusen (DE).

(74) Agent: **BIP PATENTS ASSOCIATION NO. 461**; c/o Bayer Intellectual Property GmbH Alfred-Nobel-Straße 50, 40789 Monheim am Rhein (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*

(54) Title: NOVEL FORMULATION COMPRISING ELINZANETANT IN A SOLID DISPERSION

(57) Abstract: The present disclosure relates to a pharmaceutical composition comprising a solid dispersion, the solid dispersion comprising elinzanetant (I) and at least one solid dispersion matrix comprising a neutral polymer as a solid dispersion matrix agent, its process of preparation and its use for treating diseases and disorders.



(I)

WO 2025/242583 A1